reviewed april 2026|next review october 2026|88 physicians psi has verified|50408 published studies
Mazdutide
Mazdutide is a dual GLP-1/glucagon receptor agonist developed by Innovent Biologics in China that produced approximately 14% body weight loss in Phase II, advancing through Phase III for obesity and type 2 diabetes.
Evidence landscape: 50408 published studies
50,408 published items (inflated by broad GLP-1/glucagon query). 39 human studies and 128 animal studies.
- 39 Human
- 128 Animal
- 33 Reviews
- 50208 Other research
Not FDA-approved. Phase III trials are enrolling in China and globally. No US or EU regulatory submission has been filed.
Available only through clinical trial enrollment. Not available through pharmacies in any market.
Dual GLP-1/glucagon receptor agonist, the same mechanism class as survodutide. Developed by Innovent Biologics (China) in collaboration with Eli Lilly.
PSI Assessment
Developed by Innovent Biologics in China, mazdutide is a dual GLP-1/glucagon receptor agonist that has produced approximately 14% body weight loss in Phase II trials and is advancing through Phase III in China and globally. It occupies a similar mechanistic space to survodutide but represents a separate clinical development program. The compound received particular attention because its Phase II data for obesity and type 2 diabetes was published in peer-reviewed journals, providing independently verifiable efficacy signals in the increasingly competitive next-generation obesity drug landscape.
Approximately 14% weight loss in Phase II. Dual GLP-1/glucagon mechanism. Chinese development program with global expansion.
The mechanism is dual GLP-1/glucagon receptor agonism, the same class as survodutide. GLP-1 activation suppresses appetite and improves glycemic control. Glucagon activation increases hepatic fat oxidation and energy expenditure. The combination addresses both energy intake and energy expenditure. Mazdutide's development program is distinguished by its origination in China with global expansion plans, representing the growing contribution of Chinese pharmaceutical research to the metabolic drug pipeline.
What the evidence supports
Phase II trials demonstrate approximately 14% body weight loss and meaningful glycemic improvement in type 2 diabetes. Peer-reviewed publication of Phase II data provides independently verifiable efficacy signals. The dual GCG/GLP-1 mechanism is pharmacologically validated. Phase III trials are actively enrolling in China and globally.
What is not yet established
Phase III efficacy and safety outcomes. How mazdutide compares head-to-head with survodutide, tirzepatide, or semaglutide. Whether the Chinese Phase III data will support global regulatory submissions. Long-term cardiovascular and metabolic outcomes.
Research Evidence
The findings below cover what Phase II and early Phase III data has established and where the global evidence base currently stands.
Evidence by condition
Evidence dimensions across mazdutide's investigated applications. Obesity and type 2 diabetes have Phase II and early Phase III human data. Metabolic syndrome evidence is primarily from animal studies.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Obesity | ||||
| Type 2 Diabetes | ||||
| Metabolic Syndrome |
Phase II trials demonstrated approximately 14% body weight loss with meaningful glycemic improvement in type 2 diabetes. The results were published in peer-reviewed journals.
Phase II data from Chinese populations. Whether efficacy magnitude translates across populations is not established.
The dual GCG/GLP-1 mechanism adds hepatic fat oxidation and energy expenditure beyond GLP-1 alone, with the glucagon component targeting liver fat specifically.
Same mechanism class as survodutide. The compounds have not been compared head-to-head.
Phase III trials are actively enrolling in China and globally. The GLORY-1 trial has reported Phase III weight loss results in Chinese populations.
Global approval timeline remains uncertain. Whether Chinese Phase III data will support US or EU regulatory submissions is not established.
39 Human|128 Animal|33 Reviews
View all 50408 indexed studiesHow Mazdutide Works
Mazdutide is a GLP-1/glucagon dual receptor agonist (oxyntomodulin analog) developed by Innovent Biologics in collaboration with Eli Lilly.
Like survodutide, mazdutide combines two hormone signals: GLP-1 (reduces appetite) and glucagon (burns liver fat and increases calorie burn). This dual approach targets both sides of the energy equation, reducing intake and increasing expenditure simultaneously.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Mazdutide is a GLP-1/glucagon dual receptor agonist (oxyntomodulin analog). The GLP-1 component mediates appetite suppression and glycemic control via GLP-1R activation. The glucagon component promotes hepatic lipid oxidation, thermogenesis, and energy expenditure via GCGR activation.
What is Mazdutide being studied for?
Researchers are studying Mazdutide across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Mazdutide overall. This means a compound can have human studies for one condition but only animal data for another.
Obesity
·Human TrialsPhase II data shows approximately 14% weight loss. Phase III trials are enrolling in China and globally.
Limitations: Phase III data is primarily from Chinese populations. Global regulatory submissions and approval are pending. Comparison to survodutide, tirzepatide, and retatrutide is not established.
Type 2 Diabetes
·Human TrialsPhase III glycemic data shows HbA1c improvement alongside weight loss. The dual mechanism addresses both glucose control and body weight.
Limitations: Not yet approved for diabetes in any market. Comparison to tirzepatide and semaglutide is needed.
Metabolic Syndrome
·Animal StudiesLiver fat reduction via the glucagon component positions mazdutide as a potential MASH treatment alongside its metabolic benefits.
Limitations: Liver-specific outcome data is early. Dedicated MASH trials are needed.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not approved in any market. Phase III trials are actively enrolling.
Availability: Available only through clinical trial enrollment. Not available through any pharmacy channel.
Class context: GI side effects (nausea, vomiting, diarrhea) are consistent with the GLP-1 drug class. Phase III safety data from Chinese trials shows a tolerable profile.
GI side effects (nausea, vomiting, diarrhea) are consistent with the GLP-1 drug class. Phase III safety data from Chinese trials shows a tolerable profile. The glucagon component's glucose-raising potential is counterbalanced by GLP-1 activity. Mazdutide is investigational globally.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Mazdutide discussion.
Comparison and Related Research
Mazdutide is most often compared with other dual agonists and next-generation metabolic drugs in the same competitive landscape.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Phase 2 trial evaluating mazdutide (IBI362) in Chinese adults with overweight or obesity. Over 24 weeks, mazdutide produced dose-dependent weight loss, with the highest dose group achieving clinically meaningful body weight reductions compared to placebo. Gastrointestinal side effects were the most common adverse events.Ji L et al., 2023 in Nat Commun. View on PubMed
- 2.Phase 2 trial testing mazdutide in adults with type 2 diabetes. Treatment produced significant improvements in glycemic control (HbA1c reduction) alongside body weight loss. The dual GLP-1/glucagon mechanism was associated with benefits in both glucose metabolism and weight, with a safety profile consistent with the GLP-1 receptor agonist class.Zhang B et al., 2024 in Diabetes Care. View on PubMed
- 3.Phase 1b dose-escalation trial establishing the pharmacokinetic and pharmacodynamic profile of IBI362 (mazdutide) in adults with type 2 diabetes. The study demonstrated dose-dependent glucose lowering and weight reduction, confirming target engagement at both GLP-1 and glucagon receptors in a clinical setting.Jiang H et al., 2022 in Nat Commun. View on PubMed
- 4.Review of the scientific rationale behind GLP-1/glucagon receptor dual agonism for obesity treatment. The paper explains how glucagon receptor activation increases energy expenditure and hepatic lipid oxidation while GLP-1 receptor activation suppresses appetite and improves glycemic control, creating a complementary metabolic effect that compounds like mazdutide are designed to exploit.Sanchez-Garrido MA et al., 2017 in Diabetologia. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.